Searchable abstracts of presentations at key conferences in endocrinology
Previous issue | Volume 63 | ECE2019 | Next issue

21st European Congress of Endocrinology

Lyon, France
18 May 2019 - 21 May 2019

Card image cap
18-21 May 2019, Lyon, France

Oral Communications

Anterior and Posterior pituitary 2

ea0063oc13.1 | Anterior and Posterior pituitary 2 | ECE2019

Arginine-stimulated copeptin measurements - a new test for diabetes insipidus

Winzeler Bettina , Nigro-Cesana Nicole , Refardt Julie , Vogt Deborah R , Imber Cornelia , Morin Benedict , Popovic Milica , Steinmetz Michelle , Sailer Clara , Szinnai Gabor , Chifu Irina , Fassnacht Martin , Christ-Crain Mirjam

Background: The differential diagnosis of diabetes insipidus is challenging. The most reliable diagnostic approach is hypertonic saline-stimulated copeptin measurements. However, as this test is based on the induction of hypernatremia, it is associated with adverse effects and needs close sodium monitoring. We hypothesized that arginine-stimulated copeptin measurements provide an alternative, simple and safe diagnostic test for diabetes insipidus.Methods...

ea0063oc13.2 | Anterior and Posterior pituitary 2 | ECE2019

Empagliflozin increases sodium-levels in patients with the syndrome of inappropriate antidiuretic hormone secretion – a randomized, double-blind, placebo-controlled trial

Refardt Julie , Imber Cornelia , Sailer Clara O , Jeanloz Nica , Potasso Laura , Kutz Alexander , Widmer Andrea , Urwyler Sandrine , Ebrahimi Fahim , Vogt Deborah R , Winzeler Bettina , Christ-Crain Mirjam

Introduction: The syndrome of inappropriate antidiuretic hormone secretion (SIADH) is the predominant cause of hyponatremia but the available treatment options are unsatisfying and often of little efficiency. The selective sodium-glucose co-transporter 2 inhibitor empagliflozin promotes osmotic diuresis due to glucosuria and might be a novel treatment option for SIADH.Material and methods: From September 2016 through December 2018 we randomly assigned 88...

ea0063oc13.3 | Anterior and Posterior pituitary 2 | ECE2019

Pituitary tumour-derived chemokines modulate immune cell infiltrates in the tumour microenvironment leading to aggressive phenotype

Marques Pedro , Barry Sayka , Carlsen Eivind , Collier David , Ronaldson Amy , Awad Sherine , Mendoza Nigel , Dorward Neil , Grieve Joan , Balkwill Frances , Korbonits Marta

Introduction: Tumour microenvironment (TME) is determined by non-tumoral cells, including immune, stromal or endothelial cells, and influences tumorigenesis, proliferation, invasiveness and angiogenesis. Little is known about TME in pituitary adenomas (PAs). We aimed to characterise the TME of PAs and its role in their aggressiveness, focusing on PA-infiltrating immune cells and cytokine network.Methods: Cytokine secretome from 24 human PAs (16NFPAs, 8GH...

ea0063oc13.4 | Anterior and Posterior pituitary 2 | ECE2019

Pharmacokinetics of somapacitan in individuals with hepatic impairment: an open-label, parallel group, phase 1 study

Bentz Damholt Birgitte , Dahl Bendtsen Mette , Hollensen Christian , Hojby Rasmussen Michael

Background: Somapacitan is a reversible albumin-binding growth hormone (GH) derivative developed for once-weekly administration. Non-covalent binding to endogenous albumin delays somapacitan elimination, prolonging its half-life and duration of action. Somapacitan is not cleared by a specific organ, but impaired hepatic function may affect its pharmacokinetics. We report data from an open-label, parallel group, phase I trial (NCT03212131) investigating the pharmacokinetic and ...

ea0063oc13.5 | Anterior and Posterior pituitary 2 | ECE2019

Pan-genomic classification of pituitary adenomas

Neou Mario , Villa Chiara , Armignacco Roberta , Jouinot Anne , Septier Amandine , Raffin-Sanson Marie-Laure , Perlemoine Karine , Bernier Michele , Baussart Bertrand , Bertherat Jerome , Gaillard Stephan , Assie Guillaume

Pituitary adenomas, now called pituitary neuroendocrine tumors (PitNETs), vary in histological type, secretion, invasion and growth speed. A World Health Organization (WHO) histo-prognostic classification was released in 2017. Pituitary tumorigenesis is largely unexplained. Rare germline mutations (MENIN, AIP), and common somatic mutations in somatotroph (GNAS) and corticotroph (USP8) are reported. Recently, genomic analyses have been report...